RCS - Angle PLC - RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME

AngleAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3252Ga&default-theme=true

RNS Number : 3252G  Angle PLC  28 April 2025

 For immediate release  28 April 2025

 

ANGLE plc ("the Company")

 

NEW results supportING angle's her2 assay development programme

 

ANGLE and BioView present analytical validation data confirming high
sensitivity and specificity of HER2 assay kit under development, alongside
patient case study data

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the presentation of
new data for ANGLE's HER2-CTC assay at the American Association for Cancer
Research (AACR) Annual meeting being held in Chicago.

 

ANGLE is presenting a poster on Monday 28 April 2025 between 09:00 and 12:00
(Central Time) entitled "Analytical validation of ANGLE's combined IF and FISH
assay for assessment of HER2 in circulating tumor cells" during the Liquid
Biopsy: Circulating Tumor Cells 1 session, in Poster Section 29.

 

ANGLE and BioView are developing a HER2 assay kit to work alongside the
Parsortix(®) system to assess HER2 status of CTCs from a blood sample. The
poster showcases this minimally invasive, real-time assessment for dynamic
HER2 evaluation with target analytical sensitivity and specificity of over 98%
that is linear, repeatable and reproducible.

 

Metastatic breast cancer patient data presented in the poster exemplifies that
despite HER2 negative primary tissue status, HER2 positive CTCs can be
identified in some patients at a later timepoint, suggesting their cancer may
have evolved and could benefit from HER2 targeted therapy.

 

HER2 is a protein that is associated with many cancers, particularly breast
cancer, and HER2 tumour marker testing is used to determine if HER2 targeted
therapy is likely to be effective. Current standard of care evaluates HER2
status using tissue biopsy. It is well established that HER2 status can change
over time, resulting in the original tissue biopsy assessment being out of
date. As a result, patients who could benefit from HER2 targeted treatment may
be missed.

 

Overall, these results showcase that ANGLE's HER2-CTC assay can provide
reliable and critical up to date information about the changing HER2 status of
patients which is not available through tissue biopsy alone, potentially
identifying new patients for HER2 targeted treatment.

 

 

ANGLE's Chief Scientific Officer, Karen Miller, commented:

"We are pleased to announce this new data to support HER2 CTC assessment using
the Parsortix system. Liquid biopsy assessment of CTCs enables dynamic changes
in HER2 status to be monitored in a minimally invasive way and has the
potential to help guide more effective patient treatment options."

 

This poster is available for review at:
https://angleplc.com/resources/posters/.

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGIGDSXBDDGUL